Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades
Purpose This study aimed to investigate the outcome for stage II and III rectal cancer patients compared to stage II and III colonic cancer patients with regard to 5-year cause-specific survival (CSS), overall survival, and local and combined recurrence rates over time. Methods This prospective coho...
Gespeichert in:
| Veröffentlicht in: | International journal of colorectal disease 2015-06, Vol.30 (6), p.797-806 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 806 |
|---|---|
| container_issue | 6 |
| container_start_page | 797 |
| container_title | International journal of colorectal disease |
| container_volume | 30 |
| creator | Joern, Fischer Gunter, Hellmich Thomas, Jackisch Erik, Puffer Jörg, Zimmer Dorothea, Bleyl Thomas, Kittner Helmut, Witzigmann Sigmar, Stelzner |
| description | Purpose
This study aimed to investigate the outcome for stage II and III rectal cancer patients compared to stage II and III colonic cancer patients with regard to 5-year cause-specific survival (CSS), overall survival, and local and combined recurrence rates over time.
Methods
This prospective cohort study identified 3,355 consecutive patients with adenocarcinoma of the colon or rectum and treated in our colorectal unit between 1981 and 2011, for investigation. The study was restricted to International Union Against Cancer (UICC) stages II and III. Postoperative mortality and histological incomplete resection were excluded, which left 995 patients with colonic cancer and 726 patients with rectal cancer for further analysis.
Results
Five-year CSS rates improved for colonic cancer from 65.0 % for patients treated between 1981 and 1986 to 88.1 % for patients treated between 2007 and 2011. For rectal cancer patients, the respective 5-year CSS rates improved from 53.4 % in the first observation period to 89.8 % in the second one. The local recurrence rate for rectal cancer dropped from 34.2 % in the years 1981–1986 to 2.1 % in the years 2007–2011. In the last decade of observation, prognosis for rectal cancer was equal to that for colon cancer (CSS 88.6 vs. 86.7 %,
p
= 0.409).
Conclusion
Survival of patients with colon and rectal cancer has continued to improve over the last three decades. After major changes in treatment strategy including introduction of total mesorectal excision and neoadjuvant (radio)chemotherapy, prognosis for stage II and III rectal cancer is at least as good as for stage II and III colonic cancer. |
| doi_str_mv | 10.1007/s00384-015-2219-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1682208444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714490012</galeid><sourcerecordid>A714490012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-75bacbf3d6e360f0b15ba681f34b95684c67eb8b2b6bfb519a416472aad3d91d3</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi1ERZeWH8AFWeLCJcV2HCc-VhXQlSr1Qs-WP8ZLqsTe2g5S_32dbmkBwWk8M887mvGL0HtKzigh_edMSDvwhtCuYYzKpnuFNpS3rKFMsNdoQ2gvGyq74Ri9zfmW1Fz0_A06Zp2sAt5u0P56KTbOgH1MOBe9A7zdYh1cDVucwBY9PaY2TjFgq4OFhOFu0dN0j3cxOqx9qaWSQJcZQsHjvE_xJzy-a6ytHwkAO7DaQT5FR15PGd49xRN08_XL94vL5ur62_bi_KqxvJWl6TujrfGtE9AK4omhtSAG6ltuZCcGbkUPZjDMCONNR6XmVPCeae1aJ6lrT9Cnw9y6zN0Cuah5zBamSQeIS1ZUDIyRgXNe0Y9_obdxSaFut1K0IpKzF2qnJ1Bj8LEkbdeh6ryvkKzfu1Jn_6D0evo82hjAj7X-h4AeBDbFnBN4tU_jrNO9okStLquDy6q6rFaXVVc1H54WXswM7lnxy9YKsAOQayvsIP120X-nPgAzDrBd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1681444942</pqid></control><display><type>article</type><title>Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Joern, Fischer ; Gunter, Hellmich ; Thomas, Jackisch ; Erik, Puffer ; Jörg, Zimmer ; Dorothea, Bleyl ; Thomas, Kittner ; Helmut, Witzigmann ; Sigmar, Stelzner</creator><creatorcontrib>Joern, Fischer ; Gunter, Hellmich ; Thomas, Jackisch ; Erik, Puffer ; Jörg, Zimmer ; Dorothea, Bleyl ; Thomas, Kittner ; Helmut, Witzigmann ; Sigmar, Stelzner</creatorcontrib><description>Purpose
This study aimed to investigate the outcome for stage II and III rectal cancer patients compared to stage II and III colonic cancer patients with regard to 5-year cause-specific survival (CSS), overall survival, and local and combined recurrence rates over time.
Methods
This prospective cohort study identified 3,355 consecutive patients with adenocarcinoma of the colon or rectum and treated in our colorectal unit between 1981 and 2011, for investigation. The study was restricted to International Union Against Cancer (UICC) stages II and III. Postoperative mortality and histological incomplete resection were excluded, which left 995 patients with colonic cancer and 726 patients with rectal cancer for further analysis.
Results
Five-year CSS rates improved for colonic cancer from 65.0 % for patients treated between 1981 and 1986 to 88.1 % for patients treated between 2007 and 2011. For rectal cancer patients, the respective 5-year CSS rates improved from 53.4 % in the first observation period to 89.8 % in the second one. The local recurrence rate for rectal cancer dropped from 34.2 % in the years 1981–1986 to 2.1 % in the years 2007–2011. In the last decade of observation, prognosis for rectal cancer was equal to that for colon cancer (CSS 88.6 vs. 86.7 %,
p
= 0.409).
Conclusion
Survival of patients with colon and rectal cancer has continued to improve over the last three decades. After major changes in treatment strategy including introduction of total mesorectal excision and neoadjuvant (radio)chemotherapy, prognosis for stage II and III rectal cancer is at least as good as for stage II and III colonic cancer.</description><identifier>ISSN: 0179-1958</identifier><identifier>EISSN: 1432-1262</identifier><identifier>DOI: 10.1007/s00384-015-2219-5</identifier><identifier>PMID: 25922143</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Aged ; Analysis ; Cancer ; Cancer patients ; Chemotherapy ; Colon cancer ; Colonic Neoplasms - mortality ; Colonic Neoplasms - pathology ; Colonic Neoplasms - surgery ; Drug therapy ; Gastroenterology ; Hepatology ; Humans ; Internal Medicine ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Mortality ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Original Article ; Patient outcomes ; Proctology ; Prospective Studies ; Rectal Neoplasms - mortality ; Rectal Neoplasms - pathology ; Rectal Neoplasms - surgery ; Surgery ; Survival Rate ; Treatment Outcome</subject><ispartof>International journal of colorectal disease, 2015-06, Vol.30 (6), p.797-806</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><rights>COPYRIGHT 2015 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-75bacbf3d6e360f0b15ba681f34b95684c67eb8b2b6bfb519a416472aad3d91d3</citedby><cites>FETCH-LOGICAL-c439t-75bacbf3d6e360f0b15ba681f34b95684c67eb8b2b6bfb519a416472aad3d91d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00384-015-2219-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00384-015-2219-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25922143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joern, Fischer</creatorcontrib><creatorcontrib>Gunter, Hellmich</creatorcontrib><creatorcontrib>Thomas, Jackisch</creatorcontrib><creatorcontrib>Erik, Puffer</creatorcontrib><creatorcontrib>Jörg, Zimmer</creatorcontrib><creatorcontrib>Dorothea, Bleyl</creatorcontrib><creatorcontrib>Thomas, Kittner</creatorcontrib><creatorcontrib>Helmut, Witzigmann</creatorcontrib><creatorcontrib>Sigmar, Stelzner</creatorcontrib><title>Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades</title><title>International journal of colorectal disease</title><addtitle>Int J Colorectal Dis</addtitle><addtitle>Int J Colorectal Dis</addtitle><description>Purpose
This study aimed to investigate the outcome for stage II and III rectal cancer patients compared to stage II and III colonic cancer patients with regard to 5-year cause-specific survival (CSS), overall survival, and local and combined recurrence rates over time.
Methods
This prospective cohort study identified 3,355 consecutive patients with adenocarcinoma of the colon or rectum and treated in our colorectal unit between 1981 and 2011, for investigation. The study was restricted to International Union Against Cancer (UICC) stages II and III. Postoperative mortality and histological incomplete resection were excluded, which left 995 patients with colonic cancer and 726 patients with rectal cancer for further analysis.
Results
Five-year CSS rates improved for colonic cancer from 65.0 % for patients treated between 1981 and 1986 to 88.1 % for patients treated between 2007 and 2011. For rectal cancer patients, the respective 5-year CSS rates improved from 53.4 % in the first observation period to 89.8 % in the second one. The local recurrence rate for rectal cancer dropped from 34.2 % in the years 1981–1986 to 2.1 % in the years 2007–2011. In the last decade of observation, prognosis for rectal cancer was equal to that for colon cancer (CSS 88.6 vs. 86.7 %,
p
= 0.409).
Conclusion
Survival of patients with colon and rectal cancer has continued to improve over the last three decades. After major changes in treatment strategy including introduction of total mesorectal excision and neoadjuvant (radio)chemotherapy, prognosis for stage II and III rectal cancer is at least as good as for stage II and III colonic cancer.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - surgery</subject><subject>Aged</subject><subject>Analysis</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Chemotherapy</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - mortality</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colonic Neoplasms - surgery</subject><subject>Drug therapy</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Mortality</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Original Article</subject><subject>Patient outcomes</subject><subject>Proctology</subject><subject>Prospective Studies</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - surgery</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0179-1958</issn><issn>1432-1262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU1v1DAQhi1ERZeWH8AFWeLCJcV2HCc-VhXQlSr1Qs-WP8ZLqsTe2g5S_32dbmkBwWk8M887mvGL0HtKzigh_edMSDvwhtCuYYzKpnuFNpS3rKFMsNdoQ2gvGyq74Ri9zfmW1Fz0_A06Zp2sAt5u0P56KTbOgH1MOBe9A7zdYh1cDVucwBY9PaY2TjFgq4OFhOFu0dN0j3cxOqx9qaWSQJcZQsHjvE_xJzy-a6ytHwkAO7DaQT5FR15PGd49xRN08_XL94vL5ur62_bi_KqxvJWl6TujrfGtE9AK4omhtSAG6ltuZCcGbkUPZjDMCONNR6XmVPCeae1aJ6lrT9Cnw9y6zN0Cuah5zBamSQeIS1ZUDIyRgXNe0Y9_obdxSaFut1K0IpKzF2qnJ1Bj8LEkbdeh6ryvkKzfu1Jn_6D0evo82hjAj7X-h4AeBDbFnBN4tU_jrNO9okStLquDy6q6rFaXVVc1H54WXswM7lnxy9YKsAOQayvsIP120X-nPgAzDrBd</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Joern, Fischer</creator><creator>Gunter, Hellmich</creator><creator>Thomas, Jackisch</creator><creator>Erik, Puffer</creator><creator>Jörg, Zimmer</creator><creator>Dorothea, Bleyl</creator><creator>Thomas, Kittner</creator><creator>Helmut, Witzigmann</creator><creator>Sigmar, Stelzner</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades</title><author>Joern, Fischer ; Gunter, Hellmich ; Thomas, Jackisch ; Erik, Puffer ; Jörg, Zimmer ; Dorothea, Bleyl ; Thomas, Kittner ; Helmut, Witzigmann ; Sigmar, Stelzner</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-75bacbf3d6e360f0b15ba681f34b95684c67eb8b2b6bfb519a416472aad3d91d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - surgery</topic><topic>Aged</topic><topic>Analysis</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Chemotherapy</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - mortality</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colonic Neoplasms - surgery</topic><topic>Drug therapy</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Mortality</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Original Article</topic><topic>Patient outcomes</topic><topic>Proctology</topic><topic>Prospective Studies</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - surgery</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joern, Fischer</creatorcontrib><creatorcontrib>Gunter, Hellmich</creatorcontrib><creatorcontrib>Thomas, Jackisch</creatorcontrib><creatorcontrib>Erik, Puffer</creatorcontrib><creatorcontrib>Jörg, Zimmer</creatorcontrib><creatorcontrib>Dorothea, Bleyl</creatorcontrib><creatorcontrib>Thomas, Kittner</creatorcontrib><creatorcontrib>Helmut, Witzigmann</creatorcontrib><creatorcontrib>Sigmar, Stelzner</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of colorectal disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joern, Fischer</au><au>Gunter, Hellmich</au><au>Thomas, Jackisch</au><au>Erik, Puffer</au><au>Jörg, Zimmer</au><au>Dorothea, Bleyl</au><au>Thomas, Kittner</au><au>Helmut, Witzigmann</au><au>Sigmar, Stelzner</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades</atitle><jtitle>International journal of colorectal disease</jtitle><stitle>Int J Colorectal Dis</stitle><addtitle>Int J Colorectal Dis</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>30</volume><issue>6</issue><spage>797</spage><epage>806</epage><pages>797-806</pages><issn>0179-1958</issn><eissn>1432-1262</eissn><abstract>Purpose
This study aimed to investigate the outcome for stage II and III rectal cancer patients compared to stage II and III colonic cancer patients with regard to 5-year cause-specific survival (CSS), overall survival, and local and combined recurrence rates over time.
Methods
This prospective cohort study identified 3,355 consecutive patients with adenocarcinoma of the colon or rectum and treated in our colorectal unit between 1981 and 2011, for investigation. The study was restricted to International Union Against Cancer (UICC) stages II and III. Postoperative mortality and histological incomplete resection were excluded, which left 995 patients with colonic cancer and 726 patients with rectal cancer for further analysis.
Results
Five-year CSS rates improved for colonic cancer from 65.0 % for patients treated between 1981 and 1986 to 88.1 % for patients treated between 2007 and 2011. For rectal cancer patients, the respective 5-year CSS rates improved from 53.4 % in the first observation period to 89.8 % in the second one. The local recurrence rate for rectal cancer dropped from 34.2 % in the years 1981–1986 to 2.1 % in the years 2007–2011. In the last decade of observation, prognosis for rectal cancer was equal to that for colon cancer (CSS 88.6 vs. 86.7 %,
p
= 0.409).
Conclusion
Survival of patients with colon and rectal cancer has continued to improve over the last three decades. After major changes in treatment strategy including introduction of total mesorectal excision and neoadjuvant (radio)chemotherapy, prognosis for stage II and III rectal cancer is at least as good as for stage II and III colonic cancer.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25922143</pmid><doi>10.1007/s00384-015-2219-5</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-1958 |
| ispartof | International journal of colorectal disease, 2015-06, Vol.30 (6), p.797-806 |
| issn | 0179-1958 1432-1262 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1682208444 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - surgery Aged Analysis Cancer Cancer patients Chemotherapy Colon cancer Colonic Neoplasms - mortality Colonic Neoplasms - pathology Colonic Neoplasms - surgery Drug therapy Gastroenterology Hepatology Humans Internal Medicine Medical research Medicine Medicine & Public Health Medicine, Experimental Mortality Neoadjuvant Therapy Neoplasm Recurrence, Local Neoplasm Staging Original Article Patient outcomes Proctology Prospective Studies Rectal Neoplasms - mortality Rectal Neoplasms - pathology Rectal Neoplasms - surgery Surgery Survival Rate Treatment Outcome |
| title | Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A19%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20for%20stage%20II%20and%20III%20rectal%20and%20colon%20cancer%20equally%20good%20after%20treatment%20improvement%20over%20three%20decades&rft.jtitle=International%20journal%20of%20colorectal%20disease&rft.au=Joern,%20Fischer&rft.date=2015-06-01&rft.volume=30&rft.issue=6&rft.spage=797&rft.epage=806&rft.pages=797-806&rft.issn=0179-1958&rft.eissn=1432-1262&rft_id=info:doi/10.1007/s00384-015-2219-5&rft_dat=%3Cgale_proqu%3EA714490012%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1681444942&rft_id=info:pmid/25922143&rft_galeid=A714490012&rfr_iscdi=true |